JP Morgan Chase
NXTC icon

JP Morgan Chase’s NextCure NXTC Stock Holding History

JP Morgan Chase’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107 Hold
61
– – ﹤0.01% 7537
2026
Q1 		$587 Hold
61
– – ﹤0.01% 7167
2025
Q4 		$866 Hold
61
– – ﹤0.01% 7035
2025
Q3 		$357 Sell
61
-2
-3% -$10 ﹤0.01% 7077
2025
Q2 		$348 Sell
63
-4
-6% -$21 ﹤0.01% 6734
2025
Q1 		$387 Hold
67
– – ﹤0.01% 6722
2024
Q4 		$621 Hold
67
– – ﹤0.01% 6785
2024
Q3 		$1.11K Hold
67
– – ﹤0.01% 6713
2024
Q2 		$1.28K Hold
67
– – ﹤0.01% 6581
2024
Q1 		$1.79K Sell
67
-58
-46% -$999 ﹤0.01% 6587
2023
Q4 		$1.72K Sell
125
-121
-49% -$1.75K ﹤0.01% 6744
2023
Q3 		$3.8K Buy
246
+2
+0.8% +$38 ﹤0.01% 6421
2023
Q2 		$5.26K Hold
244
– – ﹤0.01% 6165
2023
Q1 		$4K Hold
244
– – ﹤0.01% 6296
2022
Q4 		$4K Sell
244
-182
-43% -$4.19K ﹤0.01% 6208
2022
Q3 		$14K Sell
426
-2,385
-85% -$122K ﹤0.01% 5898
2022
Q2 		$159K Buy
2,811
+1,320
+89% +$68.9K ﹤0.01% 5184
2022
Q1 		$87K Buy
1,491
+760
+104% +$47.6K ﹤0.01% 5577
2021
Q4 		$53K Buy
731
+526
+257% +$44K ﹤0.01% 5922
2021
Q3 		$17K Sell
205
-3,598
-95% -$315K ﹤0.01% 6083
2021
Q2 		$367K Buy
3,803
+708
+23% +$72.4K ﹤0.01% 4890
2021
Q1 		$372K Buy
3,095
+2,450
+380% +$355K ﹤0.01% 4857
2020
Q4 		$85K Sell
645
-9,987
-94% -$1.29M ﹤0.01% 5041
2020
Q3 		$1.09M Buy
10,632
+7,703
+263% +$947K ﹤0.01% 3604
2020
Q2 		$753K Buy
2,929
+2,543
+659% +$968K ﹤0.01% 3666
2020
Q1 		$172K Sell
386
-726
-65% -$388K ﹤0.01% 4327
2019
Q4 		$752K Buy
1,112
+1,030
+1,256% +$517K ﹤0.01% 4033
2019
Q3 		$30K Sell
82
-30
-27% -$9.76K ﹤0.01% 5322
2019
Q2 		$19K Buy
+112
New +$23.3K ﹤0.01% 5452

Other funds holding NXTC

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

JP Morgan Chase's NXTC Position: Q2 2026 in Review

JP Morgan Chase held its NextCure (NXTC) position steady in Q2 2026 at 61 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #7537.

JP Morgan Chase first reported a position in NXTC in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.09M in Q3 2020. 17 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • JP Morgan Chase held 61 shares of NextCure worth $107 as of Q2 2026.
  • JP Morgan Chase left its NextCure share count unchanged in Q2 2026.
  • NextCure made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7537 holding.
  • JP Morgan Chase first reported a position in NextCure in Q2 2019 and has held it in 29 quarters since.
  • JP Morgan Chase's NextCure position peaked at $1.09M in Q3 2020.
  • 17 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.